Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
BI-3802876 in Cirrhosis, Cryptogenic: NCT07325526 Clinical Landscape Report 2026
16 September 2026
NCT07325526 clinical landscape for Cirrhosis, Cryptogenic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
QL2401 in Metabolic Dysfunction Associated Steatohepatitis: NCT07331545 Clinical Landscape Report 2026
16 September 2026
NCT07331545 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
RD-0605 in Autoimmune Encephalitis: NCT07337785 Clinical Landscape Report 2026
16 September 2026
NCT07337785 clinical landscape for Autoimmune Encephalitis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Resmetirom in Metabolic Dysfunction Associated Steatohepatitis: NCT07335601 Clinical Landscape Report 2026
16 September 2026
NCT07335601 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Mosliciguat in Familial Hypersensitivity Pneumonitis: NCT07333183 Clinical Landscape Report 2026
16 September 2026
NCT07333183 clinical landscape for Familial Hypersensitivity Pneumonitis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Plerixafor in Anemia, Sickle Cell: NCT07341022 Clinical Landscape Report 2026
16 September 2026
NCT07341022 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nintedanib esylate in Idiopathic Pulmonary Fibrosis: NCT07344558 Clinical Landscape Report 2026
16 September 2026
NCT07344558 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tegacorat in Muscular Dystrophy, Duchenne: NCT07347548 Clinical Landscape Report 2026
16 September 2026
NCT07347548 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ketamine Hydrochloride in Vaso-occlusive crisis: NCT07369024 Clinical Landscape Report 2026
16 September 2026
NCT07369024 clinical landscape for Vaso-occlusive crisis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ripertamab in Myasthenia Gravis: NCT07372807 Clinical Landscape Report 2026
16 September 2026
NCT07372807 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NB-4746 in Amyotrophic Lateral Sclerosis: NCT07369076 Clinical Landscape Report 2026
16 September 2026
NCT07369076 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
L-Glutamine in Hemoglobin SC Disease: CTRI/2026/01/102147 Clinical Landscape Report 2026
16 September 2026
CTRI/2026/01/102147 clinical landscape for Hemoglobin SC Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.